Philip Tagari - Concepedia

Author

Philip Tagari

Merck Canada Inc. (Canada)

Also Known As

P C Tagari, P Tagari, P. TAGARI, P. Tagari, P.C. Tagari, Philip C. Tagari, Philip Tagari, Tagari, P.

Publications

4.2K

Citations

H-Index

116

Concepts

All Affiliations

Merck Canada Inc. (Canada)Amgen (United States)McGill University University of Oxford Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Philip Tagari is an author at Merck Canada Inc. (Canada) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	50	2.8K
2	Natural Sciences	12	12	1.2K
3	Health Sciences	4	4	172
4	Engineering	2	2	121
5	Education	1	1	18

Philip Tagari

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Urinary Leukotriene E <sub>4</sub> Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects Pandora E. Christie, Philip Tagari, Anthony W. Ford‐Hutchinson, American Review of Respiratory Disease	1991	445
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Petpiboon Prasit, Z Wang, Christine Brideau, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryActive Cyclooxygenase-2 InhibitorPharmaceutical ScienceBiochemistry	1999	426
Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530 Daniel Dubé, Marc Blouin, Christine Brideau, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryAldehyde DehydrogenaseBiochemistryPotent 5-Lipoxygenase InhibitorsNatural Sciences	1998	271
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Melissa M. Carry, Victoria Korley, J T Willerson, Circulation	1992	172
Morphological characterization of substance P‐like immunoreactive glomeruli in the superficial dorsal horn of the rat spinal cord and trigeminal subnucleus caudalis: A quantitative study Alfredo Ribeiro‐da‐Silva, Philip Tagari, A. Claudio Cuello The Journal of Comparative Neurology	1989	136
Retrograde changes in the nucleus basalis of the rat, caused by cortical damage, are prevented by exogenous ganglioside GM1 A. Claudio Cuello, P.H. Stephens, Philip Tagari, Brain Research Developmental BiologyNeurophysiologyNeuroanatomyNucleus BasalisMedicine	1986	130
Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma J. B. Rasmussen, Lars-Olof Eriksson, DJ Margolskee, Journal of Allergy and Clinical Immunology	1992	128
Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents Roland W. Bürli, Han Xu, Xiaoming Zou, Bioorganic & Medicinal Chemistry Letters InflammationMolecular PharmacologyAnti-inflammatoryMedicineChronic Inflammation	2006	125
Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(<i>t</i>-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor Christine Brideau, Christine Chan, S. Charleson, Canadian Journal of Physiology and Pharmacology Lipid PeroxidationWhole BloodExperimental PharmacologyTranslational PharmacologyOxidative Stress	1992	112
Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells Stacia Kargman, Elizabeth Wong, Gillian Greig, Biochemical Pharmacology Selective InhibitionMolecular PharmacologyIntact CellsMolecular PhysiologySignal Transduction	1996	110

Page 1